Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans by Lwezaula, Bingileki F et al.
RESEARCH ARTICLE Open Access
Diagnostic performance of glomerular
PLA2R and THSD7A antibodies in biopsy
confirmed primary membranous
nephropathy in South Africans
Bingileki F Lwezaula1,2,3, Oluwatoyin I Ameh4, Udeme E Ekrikpo5, Francois CJ Botha6,7, Ugochi S Okpechi-Samuel8,
Nicola Wearne1,2, Pierre Ronco9, Aminu K Bello10 and Ikechi G. Okpechi1,2,10*
Abstract
Background:: Serum and tissue-based tests using phospholipase A2 receptor 1 (PLA2R) and thrombospondin type-
1 domain containing 7A (THSD7A) are established immune biomarkers for the diagnosis of primary membranous
nephropathy (PMN). This study assessed the diagnostic performance of these biomarkers in the diagnosis of PMN in
South Africans.
Methods: This was a cross-sectional analysis from a single centre in Cape Town, South Africa. Relevant biodata was
collected from all patients. Histology, including slides for PLA2R and THSD7A were processed and assessed by
typical microscopic and immunohistochemical features. Biopsy tissues of patients with membranous lupus nephritis
(LN-V) and diabetic nephropathy (DN) were used as controls. The diagnostic accuracy for diagnosis of PMN using
positive PLA2R and THSD7A were evaluated.
Results: Of the 88 patients included, 41 had PMN with a mean age of 44.5 ± 17.5 years and 61.0% were female.
Histologically, PLA2R and THSD7A were only positive in the PMN group (51.2% and 4.9%, respectively) but negative
in both control groups. The sensitivity of PLA2R and THSD7A for identifying PMN was 51.2% and 4.9%, respectively.
The sensitivity of both tests together was 53.7% while the specificity and positive predictive values (PPV) for any of
the tests (alone or in combination) was 100%. There was no difference in the sensitivity and specificity when using
PLA2R alone compared to combining the two tests (p=0.32).
Conclusion: Glomerular staining of PLA2R and THSD7A could have potential diagnostic values in South Africans.
This has implications on how immunotherapies can be initiated and used in these settings.
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Background
Membranous glomerulonephritis (MGN) is a leading
cause of the nephrotic syndrome in adults and occurs as
a primary disorder (primary membranous nephropathy
– PMN) or secondary to other disorders like lupus
nephritis, infections and certain drugs.[1–6] Primary
membranous nephropathy is a kidney-specific auto-
immune disorder in which autoantibodies develop
against self, podocyte antigens.[5] Phospholipase A2 re-
ceptor 1 (PLA2R) and thrombospondin type-1 domain
containing 7A (THSD7A) are two podocyte specific anti-
gens that have been identified in PMN.[7, 8] Determin-
ing the presence or absence of PLA2R and anti-
THSD7A antibodies in serum and renal biopsy speci-
men, has significantly reshaped the diagnostic approach
to PMN by providing important immunologic informa-
tion which aid in discriminating between primary and
secondary MGN, as well as predicting clinical outcomes
in PMN.[9] Clinically, PLA2R and anti-THSD7A anti-
gens may be identified in sera or by immunostaining
methods in renal biopsy samples. While quantitative and
semi-quantitative serologic assays are now commercially
available for PLA2R and THSD7A antibodies, it has been
noted that a significant number of individuals with his-
tologically confirmed antigens to PLA2R in glomerular
deposits (and hence a biopsy diagnosis of PMN) have
negative PLA2R serology results.[10] It has also been
shown that early in the time course of PMN, due to de-
layed seroconversion, PLA2R may be negative in serum
but demonstrable in histologic specimen.[11] Kidney bi-
opsy tissue-based testing may thus be a veritable diag-
nostic tool in appropriately identifying PMN.
The sensitivity and specificity of these tissue-based anti-
body tests in identifying PMN have largely varied across
studies. However, one meta-analysis reported a pooled
sensitivity and specificity of 65% (63–67%) and 97% (97–
98%) for serum PLA2R antibodies and 79% (76–81%) and
90% (88–92%), respectively, for glomerular PLA2R anti-
gens.[12] Hoxha et al.,[13] in a prospective cohort of 345
patients with MN reported the prevalence of THSD7A-
associated MN to be 2.6% with 92% sensitivity and a 100%
specificity using immunofluorescence techniques. Given
that MGN (both primary and secondary types due to
hepatitis B and lupus nephritis) has been shown to be a
common cause of nephrotic syndrome in adults in African
studies of kidney biopsies, differentiating primary from
secondary type is important for making therapeutic deci-
sions.[3, 6, 14] There are currently no studies in Africa
assessing the utility of serum or glomerular PLA2R or
THSD7A for accurately identifying patients with PMN.
The aim of this study is to assess the sensitivity and speci-
ficity of PLA2R and THSD7A for identifying PMN in
South African patients using kidney biopsy tissue-based
antibody tests.
Methods
Study population and study design
The study was approved by the Human Research Ethics
Committee of the University of Cape Town (HREC/REF:
662/2017). This was a cross-sectional study of patients
with native kidney biopsy proven PMN, collected con-
secutively over a 10-year period (2007 to 2016). Patients
known with lupus nephritis (LN) with biopsy proven
secondary membranous LN (LN-V) and patients with
diabetes mellitus whose biopsies showed classical fea-
tures of diabetic nephropathy (DN) were included as
controls. All the patients were selected from the renal
biopsy registry of the Division of Nephrology and Hyper-
tension, Groote Schuur Hospital (GSH), University of
Cape Town. Given the retrospective nature of this study,
patient consent was not required for this study.
Data collection
We collected relevant demographic, clinical, serological,
biochemical and histological data of all patients. Data re-
corded were age, gender, race, systolic and diastolic blood
pressures (SBP and DBP) and presence of oedema. Sero-
logical data collected include full blood count, serum cre-
atinine, estimated glomerular filtration rate (eGFR) using
the modification of diets in renal disease (MDRD) equa-
tion,[15] urine protein-creatinine ratio (UPCR), serum
cholesterol and albumin. Serologies for human immuno-
deficiency virus (HIV), Hepatitis B, syphilis and anti-
nuclear antibodies (ANA) and anti-double stranded
deoxyribonucleic acid (anti-dsDNA) were checked in all
patients to ensure that common secondary causes of
membranous nephropathy were excluded.
Histology
The diagnosis of PMN was based on typical light mi-
croscopy and immunohistochemistry (IHC) findings,
showing thickening of glomerular basement membrane
with or without spikes and granular deposition of im-
munoglobulin (Ig)G and C3 along the glomerular capil-
lary walls.[16] All patients who had been labelled as
PMN had tested negative for HIV, Hepatitis B and C,
syphilis and for all immunological markers of lupus. For
the histology, we collected data on number of glomeruli
in each biopsy, presence of tubular atrophy, interstitial
fibrosis and immunoglobulin deposits in IHC stains
(IgG, IgA, IgM, C3) as well as the results for PLA2R and
THSD7A. All histology results were entered as positive
(present) or negative (absent). All slides for PLA2R and
THSD7A were stained using standard methods as de-
scribed by manufacturers and all were analyzed and
reviewed by a single pathologist (FCJB). For the IHC
staining, we utilized methods previously described in
another study.[17] Briefly, 3 µm of formalin fixed paraf-
fin embedded sections of biopsy specimen was
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deparaffinized and rehydrated. After endogenous perox-
idase blockage and antigen retrieval, slides were incu-
bated with the antibody. For the PLA2R stain, the
antibody used was HPA012657-100UL (Sigma Aldrich,
rabbit polyclonal antibody, dilution 1:1000) and for
THSD7A, it was HPA000923-100UL (Sigma Aldrich,
rabbit polyclonal antibody, dilution 1:1000). Multiple
washes were performed, and the specimens were washed
in phosphate buffered saline (PBS) and developed in 3,
3′-diaminobenzidine (DAB). Quality control evaluation
was performed on the stained slides to confirm correct
and appropriate staining by comparison with controls.
The IHC stained slides were reviewed and assessed using
a semi-quantitative method to reveal the intensity and
position of staining i.e. by the presence of granular stain-
ing in the glomeruli by the nephropathologist.
Statistical analysis
Data analysis was performed using Stata 15.1 (StataCorp,
TX, USA). Numerical variables were reported as mean (±
standard deviation) if normally distributed and as median
(interquartile range) if skewed. Analysis of variance
(ANOVA), or its non-parametric equivalent (the Kruskall-
Wallis test) was used to compare means across groups with
pairwise comparisons performed using the Bonferroni cor-
rection. The Chi-square test was used to compare propor-
tions. The sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV), and their 95%
confidence intervals, for diagnosis of PMN using positive
PLA2R and THSD7A were calculated based on standard
methods.[18] A p-value < 0.05 was taken as significant.
Results
Demographic and Clinical Characteristics
Overall, there were eighty-eight (88) patients included in
this study: 41 with PMN, 19 with pure class V lupus
nephritis (LN-V) and 28 with diabetic nephropathy
(DN). Serologies for HIV, Hepatitis B and syphilis were
negative for all study subjects. The mean age at presen-
tation for patients with PMN was 44.5 ± 17.5 years; pa-
tients with LN-V were significantly younger (p = 0.02).
There was an overall female preponderance, however,
there was no significant gender difference observed
across groups (p = 0.07). Patients with PMN had a sig-
nificantly higher serum cholesterol (p = 0.001) and lower
serum albumin (p = 0.004) while the eGFR was lowest in
the group with DN (P = 0.001). Although the UPCR was
much higher in the PMN group, there was no significant
difference between groups (p = 0.07). Other clinical and
biochemical results are shown in Table 1.
Histologic Characteristics
The histological features of included biopsies are summa-
rized in Table 2. There were significant differences in the
number of sclerosed glomeruli, presence of tubular atro-
phy and interstitial fibrosis (all highest in the DN group).
PLA2R and THSD7A were only positive in the PMN
group (51.2% and 4.9%, respectively) and were negative in
the control groups. Only one patient with PMN showed
enhanced granular expression of both PLA2R and
THSD7A while another PMN patient who was negative
for PLA2R was positive for THSD7A. A comparison of
the demographic and clinical characteristics of PMN









Age (years) 44.5 ± 17.5 33.8 ± 13.9 46.8 ± 14.2 0.02 42.9 ± 16.4
Female gender [n (%)] 25 (61.0) 17 (89.5) 18 (64.3) 0.07 60 (68.2)
Race (Black) [n (%)] 13 (31.7) 7 (36.8) 9 (32.1) 0.92 29 (32.9)
mABP (mmHg) 94.6 ± 11.7 85.7 ± 8.0 99.4 ± 16.1 0.01 94.3 ± 13.4
Presence of oedema [n (%)] 26 (89.7) 8 (53.3) 16 (64.0) 0.02 50 (72.5)
Hb (g/dL) 11.8 ± 2.1 10.6 ± 2.3 9.9 ± 1.7 0.001 11.0 ± 2.2
Platelet count (x109/L) 368.4 ± 129.2 307.4 ± 149.4 340.9 ± 137.1 0.34 348.3 ± 135.7
WBC count (x109/L) 8.4 ± 2.4 8.5 ± 4.6 9.0 ± 3.2 0.76 8.6 ± 3.1
Total cholesterol (mmol/L) 9.3 (7.8–11.6) 4.6 (3.7–5.8) 6.3 (4.8–7.9) 0.001 7.8 (5.5–9.6)
Serum albumin (g/L) 21.8 ± 7.1 25.4 ± 7.4 28.0 ± 5.9 0.004 24.3 ± 7.3
UPCR (g/mmol creatinine) 0.87 (0.49–1.26) 0.54 (0.27–0.75) 0.52 (0.17–1.34) 0.07 0.72 (0.34–1.24)
Serum creatinine (µmol/L) 80 (63–103) 72 (51–123) 188 (97–471) 0.001 96 (66–167)
eGFR (mL/min/1.73 m2) 85 (57–124) 98 (49–137) 30 911 − 63) 0.001 68 (38–111)
PMN Primary membranous nephropathy, LN-V class V lupus nephritis, DN diabetic nephropathy, mABP Mean Arterial Blood Pressure, Hb Haemoglobin, WBC White
Blood Cell, UPCR Urine Protein Creatinine Ratio, eGFR estimated glomerular filtration rate
The 24-hour value of proteinuria (g/24Hrs) is approximately 10-times the ratio of the UPCR in g/mmol creatinine
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Number of glomeruli per view (n [IQR]) 15 (10–21) 16 (8–20) 16 (10–26) 0.47 15 (10–23)
Sclerosed glomeruli (n) 0.0 (0.0-6.7) 0.0 (0.0-2.6) 22.5 (8.4–48.7) 0.001 0.0 (0.0-14.8)
Tubular atrophy [n (%)] 7 (17.1) 4 (21.1) 18 (64.3) < 0.001 29 (32.9)
Interstitial fibrosis [n (%)] 12 (29.3) 7 (36.8) 26 (92.9) < 0.001 45 (51.1)
Immunohistochemistry:
• IgG [n (%)] 31 (75.6) 16 (84.2) 4 (14.3) < 0.001 51 (57.9)
• IgA [n (%)] 9 (21.9) 7 (36.8) 1 (3.6) 0.02 17 (19.3)
• IgM [n (%)] 16 (39.0) 13 (68.4) 8 (28.6) 0.02 37 (42.1)
• C3 [n (%)] 31 (75.6) 10 (52.6) 7 (25.0) < 0.001 48 (54.5)
PLA2R (positive) 21 (51.2) 0 (0.0) 0 (0.0) < 0.001 21 (23.9)
THSD7A (positive) 2 (4.9) 0 (0.0) 0 (0.0) 0.31 2 (2.3)
PMN Primary membranous nephropathy, LN-V class V lupus nephritis, DN diabetic nephropathy, IQR Interquartile range; IgA Immunoglobulin A,
IgG Immunoglobulin G, IgM Immunoglobulin G, C3 Complement factor 3; PLA2R phospholipase A-2 receptor; THSD7A thrombospondin type-1 domain
containing 7A






Age (years) 44.71 ± 14.93 43.90 ± 20.46 0.88
Female gender [n (%)] 11 (52.38) 14 (70.00) 0.25
Race (Black) [n (%) 7 (33.33) 14 (66.67) 0.82
mABP (mmHg) 93.7 ± 10.8 95.48 ± 12.91 0.65
Presence of oedema (%) 12 (57.1) 14 (70.0) 0.39
Hb (g/dl) 12.1 ± 1.9 11.5 ± 2.2 0.35
Platelet count (x109/L 363.3 ± 147.5 374.7 ± 106.4 0.79
WBC count (x109/L) 7.8 ± 2.0 9.2 ± 2.7 0.06
Total cholesterol (mmol/L) 10.6 ± 4.2 8.9 ± 3.5 0.25
Serum albumin (g/L) 22.8 ± 6.3 20.5 ± 7.9 0.34
UPCR (g/mmol creatinine) 0.9 (0.7–1.1) 0.8 (0.4–1.3) 0.65
Serum creatinine (µmol/L) 88.0 (64.0–106.0) 77.5 (61.0–101.0) 0.50
eGFR (mL/min/1.73 m2) 85.0 (54.0–111.0) 85.5 (60.0–131.5) 0.57
Tubular atrophy [n (%)] 5 (23.8) 2 (10.0) 0.24
Interstitial fibrosis [n (%)] 5 (23.8) 7 (35.0) 0.43
IgG positive [n (%)] 18 (85.7) 13 (65.0) 0.12
IgA positive [n (%)] 5 (23.8) 4 (20.0) 0.77
IgM positive [n (%)] 11 (52.4) 5 (25.0) 0.07
C3 positive [n (%)] 17 (80.9) 14 (70.0) 0.41
mABP Mean Arterial Blood Pressure; Hb Haemoglobin; WBC White Blood Cell; UPCR Urine Protein Creatinine Ratio; eGFR estimated glomerular filtration rate;
IgA Immunoglobulin A; IgG Immunoglobulin G; IgM Immunoglobulin M; C3 Complement factor 3; PLA2R phospholipase A-2 receptor
The 24-hour value of proteinuria (g/24Hrs) is approximately 10-times the ratio of the UPCR in g/mmol creatinine
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patients with positive and negative expression of PLA2R
in their biopsies is shown in Table 3. There were no iden-
tified demographic or clinical differences between both
groups.
Comparison of PLA2R positive PMN and class V LN
Table 4 shows the clinical and histological features of
patients with positive PLA2R and LN-V group. Both
serum cholesterol (p = 0.002) and UPCR (P = 0.04) were
significantly higher in the positive PLA2R group. There
were no significant differences in the histological fea-
tures between both groups.
Sensitivity and Specificity of PLA2R and THSD 7A for
idiopathic membranous nephropathy
Table 5 provides a summary of the sensitivity, specificity,
positive and negative predictive values of enhanced ex-
pression of PLA2R and THSD7A (alone and in combin-
ation) for predicting PMN. PLA2R and THSD7A (alone
or when combined) showed a specificity and positive
predictive values (PPV) of 100%. The sensitivity (alone
or combined) of PLA2R and THSD7A were 51.2%
[95%CI 35.1% − 67.1%], 4.9% [95%CI 0.6% − 16.5%] and
53.7% [95%CI 37.4% − 69.3%] respectively. There was no
difference in the sensitivity and specificity when using
PLA2R alone compared to combining the two tests (p =
0.32) (analysis not shown).






Age (years) 44.71 33.8 ± 13.9 0.02
Female gender [n (%)] 11 (52.4) 17 (89.5) 0.01
Race (Black) [n, %] 7 (33.3) 7 (36.8) 0.82
mABP (mmHg) 93.7 ± 10.8 85.7 ± 8.0 0.03
Presence of oedema [n (%)] 12 (57.14) 8 (42.11) 0.34
Hb (g/dL) 12.1 ± 1.9 10.6 ± 2.3 0.03
Platelet count (x109/L) 363.3 ± 147.5 307.4 ± 149.5 0.28
WBC count (x109/L) 7.8 ± 2.0 8.5 ± 4.6 0.53
Total cholesterol (mmol/L) 9.9 (8.7–11.8) 4.6 (3.7–5.8) 0.002
Serum albumin (g/L) 22.8 ± 6.28 25.45 ± 7.35 0.30
UPCR (g/mmol creatinine) 0.9 (0.7–1.1) 0.54 (0.3–0.8) 0.04
Serum creatinine (µmol/L) 88.0 (64.0–106.0) 72.0 (51.0–123.0) 0.65
eGFR (mL/min/1.73 m2) 85.0 (54.0–111.0) 98.0 (49.0–137.0) 0.74
Number of glomeruli per view (n) 14 (10–20) 16 (8–20) 0.97
Tubular atrophy [n (%)] 5 (23.8) 4 (21.1) 0.83
Interstitial fibrosis [n (%)] 5 (23.8) 7 (36.8) 0.37
Immunohistochemistry:
• IgG [n (%)] 18 (85.7) 16 (84.2) 0.89
• IgA [n (%)] 5 (23.8) 7 (36.8) 0.37
• IgM [n (%)] 11 (52.4) 13 (68.4) 0.30
• C3 [n (%)] 17 (80.9) 10 (52.6) 0.06
mABP Mean Arterial Blood Pressure; Hb Haemoglobin; WBC White Blood Cell; UPCR Urine Protein Creatinine Ratio; eGFR estimated glomerular filtration rate;
IgA Immunoglobulin A; IgG Immunoglobulin G; IgM Immunoglobulin M; C3 Complement factor 3; PLA2R phospholipase A-2 receptor
The 24-hour value of proteinuria (g/24Hrs) is approximately 10-times the ratio of the UPCR in g/mmol creatinine
Table 5 Sensitivity, specificity, PPV and NPV of PLA2R and THSD7A
Sensitivity Specificity PPV NPV
PLA2R 51.2 (35.1–67.1) 100 (92.5–100) 100 (83.9–100) 96.7 (95.5–97.5)
THSD7A 4.9 (0.6–16.5) 100 (92.5–100) 100 (93.3–94.1) 93.7 (93.3–94.1)
PLA2R & THSD7A 53.7 (37.4–69.3) 100 (92.5–100) 100 (84.6–100) 71.2 (58.7–81.7)
All values are presented as percentage and (95% confidence interval); PPV positive predictive value; NPV Negative predictive value; PLA2R phospholipase A-2
receptor; THSD7A thrombospondin type-1 domain containing 7A
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Discussion
With the identification of candidate podocyte antigen
targets such as PLA2R and THSD7A and their respective
PLA2R and anti-THSD7A autoantibodies, the auto-
immune basis of MGN has effectively been established.
Our study aimed to determine the occurrence of novel
antigens associated with MGN among South African pa-
tients previously defined as PMN by standard micro-
scopic techniques. We found a respective frequency of
occurrence of positive glomerular staining for PLA2R
and THSD7A in 51.2% (21/41 patients) and 4.9% (2/41
patients) of biopsies initially categorized as PMN. None
of the biopsies of LN-related MGN or DN stained posi-
tively for either PLA2R or THSD7A.
Since the canonical work of Beck et al. [7] in which
the autoimmune target podocyte antigen PLA2R was
discovered, the prevalence of PLA2R antibody in serum
and/or PLA2R antigen in kidney tissue deposits in PMN
have been variously described among different popula-
tions. In our cohort of predominantly non-black South
Africans, the frequency of occurrence of histologic auto-
antibody positivity was relatively low at 51.2% compared
to data from European cohorts in whom rates from
69.2–73.8% have been observed.[10, 19] Among Japanese
patients however, lower rates as seen in our study have
also been reported.[20] Evidence continues to accrue for
a genetic component in the pathogenesis of PMN and a
genetic role in the varying prevalence observed particu-
larly with respect to PLA2R autoantibody positivity
across different ethnicities. HLA-DQA1 and PLA2R1 are
risk alleles for PMN that have been identified and dem-
onstrated to confer different disease risk in different
populations with a strong association shown among
European, Indian, Chinese but not African Americans
patients.[21–23].
Approximately 1 in 2 patient histologic samples initially
identified as PMN by standard microscopic techniques
did not demonstrate enhanced glomerular immune de-
posits staining for PLA2R antigen. This PLA2R immune
deposit negative state could be accounted for by either of
two possibilities. It is probable that these are indeed PMN
cases with yet to be identified target podocyte antigen(s)
as research continues to identify other candidate glomeru-
lar antigens that are autoimmune targets in PMN. Indeed
1 of our 20 PLA2R negative patients had a positive glom-
erular immune deposit staining for THSD7A, an antigenic
target that was identified 6 years after PLA2R. Other novel
proteins including neural epidermal growth factor-like 1
protein (NELL-1) [24] and Semaphorin 3B [25] have re-
cently been identified to be associated with membranous
nephropathy. NELL-1 was present in 23% [29/126] of
European PLA2R and THSD7A negative PMN patients
while Semaphorin 3B was predominantly present in paedi-
atric patients with MGN.[24, 25].
These discoveries lend credence to our hypothesis that
other glomerular basement membrane antigens may well
underly the pathogenesis of PMN in this African cohort,
especially with our relatively younger group of patients.
An alternate explanation could be that these are second-
ary cases of MGN currently misidentified as PMN as
predisposing factors such as in chronic viral infections
like chronic hepatitis B, autoimmune disorders such as
LN and solid organ malignancies were not clinically ap-
parent and detectable by routine checks at the time of
renal biopsy. Hepatitis-B associated glomerular disease
and LN constitute the two commonest causes of second-
ary GNs in Africa and in both entities glomerular disease
has been known to occur in the absence of systemic evi-
dence of chronic hepatitis B antigenemia and lupus se-
rologies respectively.[3, 26] We however could not
demonstrate any significant clinical or histologic differ-
ences between our PLA2R positive and PLA2R negative
patients to suggest that they represent two distinct
pathogenetic groups of patients (Table 3). Unfortunately,
we were unable to stain the biopsies for exostosin which
can detect cases labelled as PMN but related to LN.
Sethi et al.[27] detected exostosin 1 (EXT1) and exosto-
sin 2 (EXT2) in 21 cases of PLA2R-negative MN, but
not in PLA2R-associated MN and control cases, suggest-
ing that subset of MN is associated with accumulation
of EXT1 and EXT2 in the GBM. Thus, a yet to be iden-
tified glomerular antigen in this African group of PMN
patient may be a more probable theory underlying
PLA2R negative immune deposit staining. It is also pos-
sible, although we used an IHC method that has been
previously described, that methodological differences in
IHC techniques could have contributed to the propor-
tion of PLA2R positive biopsies in our group.
Distinguishing between PMN and LN-V histologi-
cally has traditionally rested upon the additional dem-
onstration of subendothelial deposits, mesangial
hypercellularity and positive IHC/IF staining for C3,
C1q, IgM, IgA and IgG1/IgG3 subclass in LN-V biop-
sies. Positive staining for glomerular PLA2R antigen
by IF/IHC has now been added to the armamentar-
ium of diagnostic tools in differentiating between
PMN and LN-V with the latter typically, but not al-
ways, demonstrating negative serum PLA2R antibodies
and/or glomerular staining for the PLA2R antigen.[28]
Although we were not able to subtype IgG class or
stain for C1q, we could not broadly exemplify this
differential IHC staining pattern between our PMN
patients and LN-V patients (Table 4). Although im-
munofluorescence examination can aid in differentiat-
ing LN-V from PMN given the absence of IgM, IgA,
and C1q in the latter, it has been noted that these
differences can be challenging due to the overlap that
can occur.[20, 29] This may explain the presence, in
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a few PMN patients, of positive IgA, IgM and C1q
despite these patients testing negative for all common
secondary causes of MGN. Based on our findings
there were notable clinical differences between PLA2R
positive patients and LN-V patients with PLA2R pa-
tients having 1.7 fold heavier proteinuria and more
than 2-fold higher total serum cholesterol levels than
lupus MN patients; as is typical for the demographic
epidemiology of lupus, there was a female predispos-
ition for lupus. Dual positivity for the glomerular
PLA2R and THSD7A antigens in patients with PMN
is being increasingly reported from some studies.[30,
31] Only one patient in our cohort demonstrating
dual positivity was demonstrated. It remains unclear
the clinical implications of this dual staining pattern.
Our study is not without its limitations. Firstly, we
were unable to stain the PLA2R negative samples for
EXT1 and EXT 2, especially considering the younger age
of patients in our study. This may have shown, as others
have done in recent studies,[27] that some PLA2R nega-
tive patients treated as PMN could be patients with LN.
Additionally, there was no outcome data reported for
the patients to evaluate the role of glomerular PLA2R or
THSD7A reactivity with response to therapy and disease
progression. Our study was not designed to do this as
we wanted to assess the relevance of these tests in an Af-
rican population given that there are no previous studies.
Furthermore, we were also unable to include the biop-
sies of patients with cancers and secondary MN to assess
if THSD7A shows any association in such patients in
our population. Lastly, we did not have serum samples
at the time of diagnosis of MGN to assess serum PLA2R
antibodies and determine if there existed any correlation
between serum PLA2R antibodies and glomerular stain-
ing in our PLA2R positive patients. Despite these limita-
tions and given the high specificity and PPV of our
study results, it shows that glomerular PLA2R and
THSD7A staining can be used for identifying PMN in
African patients with MGN. We also encourage outcome
studies using these tests in patients with biopsy proven
PMN as this will improve the use of appropriate therap-
ies for treating patients.
Conclusions
This study shows that glomerular staining of PLA2R
and THSD7A can be used to identify patients with
PMN in South African patients with biopsy proven
MGN. This means that immunotherapies for such pa-
tients can be appropriately initiated and judiciously
monitored. Our study also showed that a combination
of PLA2R and THSD7A may not provide better diag-
nostic accuracy compared to PLA2R only and that
PMN patients with positive glomerular staining for
PLA2R tend to have a more severe form nephrotic
syndrome evidenced by higher UPCR compared with
PLA2R-negative patients. There is need for further
studies in other African populations to assess if glom-
erular and/or serum PLA2R and THSD7A can be
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